224,514 results on '"Diffuse large B-Cell lymphoma"'
Search Results
2. Efficacy and safety of the thiotepa–busulfan conditioning regimen as for autologous stem cell transplantation in relapsed/refractory systemic diffuse large B cell lymphoma: a single-center retrospective study: Efficacy and safety of the thiotepa–busulfan conditioning…
3. Baseline 18F-FDG PET/CT radiomics for prognosis prediction in diffuse large B cell lymphoma with extranodal involvement
4. TGFBI regulates the TGF-β pathway to affect the malignant progression and cisplatin sensitivity in diffuse large B-cell lymphoma
5. Epcoritamab-Induced fatal pleural effusion in diffuse large B-Cell lymphoma: a case report and literature review
6. Targeting refractory diffuse large B cell lymphoma by CAR-WEE1 T-cells: In vitro evaluation
7. Validation of prognostic models in elderly patients with diffuse large B-cell lymphoma in a real-world nationwide population-based study – development of a clinical nomogram
8. The metabolic role of lactate dehydrogenase in the growth of diffuse large B cell lymphoma
9. The efficacy and safety of ZR2 versus R-CHOP-like for elderly patients with newly diagnosed diffuse large B cell lymphoma: a single-center prospective study in China
10. Outcome of patients with diffuse large B-cell lymphoma and testicular involvement – real world data
11. MYC-dependent MiR-7-5p regulated apoptosis and autophagy in diffuse large B cell lymphoma by targeting AMBRA1
12. Plant Virus Intratumoral Immunotherapy with CPMV and PVX Elicits Durable Antitumor Immunity in a Mouse Model of Diffuse Large B‑Cell Lymphoma
13. Primary central nervous system diffuse large B-cell lymphoma with MYC and BCL2 rearrangements associated with deep brain stimulation device
14. Non-linear relationship between soluble interleukin-2 receptor and prognosis of diffuse large B-cell lymphoma
15. Diffuse large B-cell lymphoma of the gallbladder with hepatoduodenal invasion exhibiting a necrotic tendency
16. Tumour-associated macrophages in diffuse large B-cell lymphoma: the prognostic and therapeutic impact in a South African centre with high HIV seroprevalence
17. Analysis of CCND3 mutations in diffuse large B-cell lymphoma
18. A retrospective analysis of the clinicopathological features and prognostic value of MAPK12 protein expression in diffuse large B-cell lymphoma
19. Diffuse Large B-Cell Lymphoma – Experience from a Tertiary Care Hospital in Eastern India
20. A rare case of splenic marginal zone lymphoma with MYD88 mutation transformed into diffuse large B-cell lymphoma: case report and literature review
21. A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel versus Tisagenlecleucel in the Treatment of Diffuse Large B-cell Lymphoma Based on a Real-World French Registry
22. Modulating JAK2/STAT3 signaling by quercetin in Qiling Baitouweng Tang: a potential therapeutic approach for diffuse large B-cell lymphoma
23. Benefit of consolidative radiation in patients with extranodal limited-stage diffuse large B-cell lymphoma: a multicenter retrospective study in China
24. Identification of intratumoral microbiome-driven immune modulation and therapeutic implications in diffuse large B-cell lymphoma
25. Spatial transcriptomics reveals prognostically LYZ+ fibroblasts and colocalization with FN1+ macrophages in diffuse large B-cell lymphoma
26. Metabolic tumor volume from baseline [18 F]FDG PET/CT at diagnosis improves the IPI stratification in patients with diffuse large B-cell lymphoma
27. The gut microbiota is altered significantly in primary diffuse large b-cell lymphoma patients and relapse refractory diffuse large b-cell lymphoma patients
28. Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting As Indolent Lymphoma (REVERSE_2021)
29. Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
30. An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
31. Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
32. Diffuse large B-cell lymphoma presenting as acute lumbosacral plexopathy with persistent lower back pain and fatigability
33. Transdifferentiation of diffuse large B-cell lymphoma to a poorly differentiated neoplasm following CAR T-cell therapy
34. Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma
35. The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma
36. The Role of Platelet to Lymphocyte Ratio (PLR) in Predicting Early Treatment Response in Diffuse Large B Cell Lymphoma
37. Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma
38. Maxillary Diffuse Large B-Cell Lymphoma Enshrouded as Osteomyelitis: A Case Report
39. USP13 promotes proliferation and angiogenesis of diffuse large B-cell lymphoma cells by promoting MCL-1 expression
40. “Bone marrow–liver–spleen-type diffuse large B-cell lymphoma” presenting with cold autoimmune hemolytic anemia: a case report
41. Pan-immune-inflammation value and body mass index to predict survival in diffuse large B-cell lymphoma
42. MYCT1 inhibits hematopoiesis in diffuse large B-cell lymphoma by suppressing RUNX1 transcription
43. Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
44. The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide (CLL1818)
45. Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
46. Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
47. TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
48. Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
49. QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
50. Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.